Philip Huxley

Philip Huxley has a diverse work experience in the pharmaceutical and biotech industry. Philip is currently serving as the Vice President Oncology at Bicycle Therapeutics since 2022. Prior to this role, they founded and directed Gateway Pharma Ltd. from 2006 to 2022, where they managed drug discovery programs and positioned assets for sale. From 2015 to 2022, they co-founded Ducentis Biotherapeutics Ltd., a pre-clinical stage company focused on developing therapies for inflammation and autoimmune diseases. Philip also served as the Chief Technology Officer at Prexa Pharmaceuticals Inc. from 2011 to 2015, where they investigated the use of dopamine selective reuptake inhibitors. Furthermore, they founded and directed Gateway Specialty Chemicals Ltd. from 2010 to 2014, and Ampla Pharmaceuticals Inc. from 2011 to 2014. Philip also worked as a Medicinal Chemistry Advisor at Spear Therapeutics Inc. from 2006 to 2011. Earlier in their career, they held positions as Senior Director of Drug Discovery at Galapagos Genomics in 2004 and Head of Drug Discovery at Avidex Limited from 2000 to 2004. Philip started their career as the Head of Molecular Design at British Biotech from 1990 to 1999.

Philip Huxley pursued their education in a chronological manner. Philip began their academic journey at the University of Aberdeen from 1975 to 1979, where they obtained a Bachelor of Science degree in Chemistry. Five years later, they continued their studies at the University of Sussex from 1980 to 1983. Here, they completed a D.Phil degree, specializing in Computational Chemistry.